Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SMEs contacted US FDA's drug ombudsman more often than big pharma in 2011

This article was originally published in SRA

Executive Summary

The ombudsman for the US Food and Drug Administration's drugs centre witnessed a 55% increase in contacts from commercial sponsors in 2011 compared to the previous year1. Most of these commercial sponsors were small and medium-sized entities, who contacted the ombudsman when their drug development plans hit a snag.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS116794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel